- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.09. | Curanex Pharmaceuticals Inc - 8-K, Current Report | 5 | SEC Filings | ||
| 17.08. | Curanex Pharmaceuticals Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 21.07. | Curanex Pharmaceuticals Inc - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 14.05. | Curanex Pharmaceuticals Inc: Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission | 252 | GlobeNewswire (Europe) | Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated... ► Artikel lesen | |
| 14.05. | Curanex Pharmaceuticals Inc - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| CURANEX PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 07.05. | Curanex Pharmaceuticals Inc - 8-K, Current Report | - | SEC Filings | ||
| 08.04. | Curanex Pharmaceuticals Inc: Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline | 289 | GlobeNewswire (Europe) | Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease According to patient accounts, multiple critically... ► Artikel lesen | |
| 08.04. | EXCLUSIVE: Penny Stock Curanex Expands Cachexia Focus Backed By Patient Recovery Narratives | 1 | Benzinga.com | ||
| 06.04. | Curanex Pharmaceuticals Inc: Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care | 1 | GlobeNewswire (USA) | ||
| 06.04. | EXCLUSIVE: Curanex Highlights Case Study Supporting Cachexia Focus In Oncology Strategy | 1 | Benzinga.com | ||
| 02.04. | Curanex Pharmaceuticals Inc: Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company's Evolution Into a Broader Therapeutics Development ... | 403 | GlobeNewswire (Europe) | Company expands strategic focus into one of oncology's most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) ("Curanex"... ► Artikel lesen | |
| 02.04. | EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases | 2 | Benzinga.com | ||
| 02.04. | Curanex Pharmaceuticals Inc - 8-K, Current Report | 2 | SEC Filings | ||
| 30.03. | Curanex Pharmaceuticals Inc: Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission | 493 | GlobeNewswire (Europe) | Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform Jericho, New York, March 30, 2026 (GLOBE NEWSWIRE) -- Curanex... ► Artikel lesen | |
| 30.03. | Curanex Pharmaceuticals Inc - 10-K, Annual Report | - | SEC Filings | ||
| 18.03. | Curanex Pharmaceuticals Inc: Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission | 285 | GlobeNewswire (Europe) | Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum Feasible Dose, Enabling Advancement to GLP Toxicology Program Jericho, New York, March... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASSEMBLY BIOSCIENCES | 25,800 | +0,39 % | Assembly Biosciences zieht Milliarden-Option: Countdown auf den 15. Oktober gestartet | Bei Assembly Biosciences spitzt sich die Investmentstory deutlich zu. Mein Biotech-Favorit hat gegenüber seinem Pharmapartner Gilead seine Option ausgeübt, sich mit 40 Prozent an den US-Entwicklungskosten... ► Artikel lesen | |
| AMARIN | 12,000 | +0,84 % | Amarin Corporation plc: Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence | Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA's... ► Artikel lesen | |
| COMPASS PATHWAYS | 12,400 | 0,00 % | Eli Lilly, AbbVie und Johnson & Johnson: Wie der Fünf-Milliarden-Dollar-Pharma-Run auf Psychedelika Emyria in den Fokus rückt | ||
| ALTIMMUNE | 2,850 | +1,24 % | Altimmune, Inc: Altimmune Announces Second Quarter 2026 Financial Results and Business Update | Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 6,050 | -0,82 % | Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates | Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 6,960 | -0,78 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer | NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage company focused on developing promising new therapies... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 13,850 | 0,00 % | Alliance Advisors LLC: Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences | Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) on the successful completion of its tender offer... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 1,295 | -0,38 % | Biodexa Pharmaceuticals PLC: Interim results for the six months ended June 30, 2026 | September 11, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2026 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| ARTIVION | 21,200 | -1,85 % | Artivion, Inc.: Artivion Reports Second Quarter 2026 Financial Results | Second Quarter & Recent Business Highlights:
Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025... ► Artikel lesen | |
| ATYR PHARMA | 0,371 | 0,00 % | aTyr Pharma, Inc.: aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis | SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 4,712 | +2,79 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) | WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory... ► Artikel lesen | |
| AVALO THERAPEUTICS | 14,160 | +1,72 % | Avalo Therapeutics: Strategie für IL-1-Beta-Plattform nach starken Phase-II-Daten | ||
| AKARI THERAPEUTICS | 11,115 | -1,64 % | Akari Therapeutics Plc: Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums | ||
| BIOHAVEN | 11,275 | +2,83 % | FDA places partial hold on Biohaven's epilepsy drug | ||
| AQUESTIVE THERAPEUTICS | 4,775 | -0,10 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Successfully completed human factors validation study and pharmacokinetic study for Anaphylm (dibutepinephrine) sublingual filmRemains on track to resubmit Anaphylm NDA to the FDA in Q3 2026Continues... ► Artikel lesen |
CURANEX PHARMACEUTICALS INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,070 (+1,57 %) liegt der Kurs bei 4,520 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CURANEX PHARMACEUTICALS INC finden Sie auf Wallstreet Online.